Orca-T Allogeneic Cell Therapy — PatSnap Eureka
Orca-T and Next-Generation Allogeneic Cell Therapy for AML, ALL & MDS
Acute GVHD of Grade 2–4 strikes 40–50% of unrelated donor PBSC transplant recipients. Discover how Orca-T's Treg/Tcon precision graft, CD33KO eHSPC, HA-1/HA-2 TCR-T cells, and eight other pipeline modalities are rewriting the GVHD reduction playbook — mapped from global patent filings.
Pipeline Stage Distribution
10 modalities across AML, ALL & MDS GVHD reduction — by development stage
Orca-T: Precision Treg/Tcon Graft Engineering
Orca-T, developed by Orca Biosystems, Inc., represents the most clinically advanced Treg-based precision allogeneic cell therapy in this patent dataset. The mechanism involves preparing a composite graft containing highly purified, polyclonal donor Tregs — which suppress alloreactive immune responses — administered alongside a defined conventional T cell (Tcon) fraction that maintains anti-tumor and anti-infection immunity. Naive conventional αβ-T cells are selectively depleted from the graft while memory T cells are preserved.
A critical paradigm shift documented in Orca Biosystems filings across CA, BR, JP, and CN jurisdictions is the move from dual-agent GVHD prophylaxis (tacrolimus + methotrexate) to Orca-T plus single-agent tacrolimus, reducing immunosuppressive burden and potentially allowing earlier immune reconstitution and stronger graft-versus-leukemia (GvL) activity. As the filings state: "Strategies for reducing GVHD are limited in efficacy or are affected by increased risk of infection and relapse."
Patent filings embed data from two prospective studies: NCT01660607 (Phase 2, single-center, n=34) and NCT04013685 (Phase 1b, multi-center, n=103). The combined 137 patients had ≥100-day follow-up (range 27–1,988 days; median 341 days). Myeloablative conditioning was predominantly busulfan-based (n=99) or TBI-based (n=38). GVHD and relapse-free survival (GRFS) at 1 year was superior to the CIBMTR historical comparator (n=375). According to WIPO-indexed filings, Orca Biosystems has prosecuted IP across five jurisdictions, signaling active global freedom-to-operate strategy.
Orca-T Clinical Outcomes & Pipeline Landscape
Key metrics extracted from Orca Biosystems patent filings and cross-pipeline assignee analysis via PatSnap Analytics.
Orca-T Key Clinical Metrics vs Standard of Care
Engraftment kinetics and patient cohort sizes from embedded Phase 1b/2 data in Orca Biosystems patent filings compared to CIBMTR historical benchmark.
Standard GVHD Incidence & Orca-T Prophylaxis Context
Acute GVHD Grade 2–4 in standard unrelated donor PBSC transplants and GVHD incidence despite CNI+methotrexate, per patent-embedded clinical references.
GVHD Reduction Approaches Across AML, ALL & MDS
From Treg-based graft engineering to antigen-shielded HSPCs and pharmacological GvL enhancers — mapped from global patent filings analyzed via PatSnap.
Extended Orca Platform: Tri-Component Graft (HSPC + Treg + Tmem)
A 2025 CN filing extends the platform to include enriched HSPC, Tregs, and memory T cells (Tmem), with depletion of naive CD3+CD25−CD45RA+ Tcons. Tacrolimus is specified as a single-agent GVHD prophylactic maintained above threshold concentration for up to approximately 180 days.
Preclinical Extension / Clinical ParentMulti-Donor CD4-IL-10 T Cells for Off-the-Shelf GvHD Suppression
Multi-donor CD4-IL-10 cell populations generated from ≥2 T cell donors to express IL-10. Preclinical data show injection of 2.5×10^6 cells on Day 3 after ALL-CM myeloid leukemia cell injection in NSG mice produced durable leukemia-free survival, preserving GvL while suppressing GvHD.
Preclinical In VivoTCR-Engineered T Cells Targeting HA-1 & HA-2 Minor Histocompatibility Antigens
Engineered T cells expressing TCRs specific for HA-1 and HA-2, which are expressed on hematopoietic cells including AML, ALL, and MDS blasts but not non-hematopoietic tissues. Explicitly post-transplant in intent, targeting residual or relapsed disease with minimized GVHD risk.
Preclinical / Early StageCD33KO eHSPC + Gemtuzumab Ozogamicin (Mylotarg) ADC Combination
Donor HSPCs are genetically engineered to delete CD33 expression, rendering the normal hematopoietic compartment insensitive to CD33-directed ADC therapy. Manufacturing acceptance criteria: CD33 editing efficiency ≥45% and cell viability ≥70% at 48 hours post-electroporation. Enables full-dose Mylotarg post-transplant.
IND-Enabling / Early ClinicalNKG2D Ligand-Targeting Chimeric Receptor Immune Cells for AML/MDS
Engineered immune cells expressing chimeric receptors targeting NKG2D ligands — stress-induced surface antigens upregulated on AML and MDS cells. Dosing regimens include lymphodepletion preceding each ~21–28 day cycle, with consolidation for responders and re-treatment for progressors. Response categories: CR, CRi, PR.
Clinical Stage ReferencedAnti-OX40L Antibodies for Prophylactic GvHD Prevention
Anti-human OX40L antibodies administered prophylactically peri-transplant: 1–3 days pre-transplant at ~8 mg/kg IV, followed by biweekly dosing. Biomarker-guided administration using TNFR1, ST-2, elafin, IL-2Rα, and Reg3α to trigger treatment only when GVHD risk thresholds are exceeded.
Preclinical / Early ClinicalTargeted Agents Interfacing with the Transplant Setting
Beyond cellular engineering, patent filings cover antibody and small-molecule strategies addressing GVHD prevention, gut-homing blockade, and post-transplant GvL enhancement.
Explore the full allogeneic cell therapy patent landscape
PatSnap Eureka maps every assignee, jurisdiction, and claim across the GVHD reduction pipeline in real time.
Next Frontier: Dual GVHD Suppression + Relapse Prevention
Retrieved patent signals identify combination approaches that address the competing risks of GVHD and relapse simultaneously — a gap single-modality approaches have not yet fully closed. See how R&D teams use PatSnap to track these signals.
Orca-T + Single-Agent Tacrolimus
The Orca Biosystems filings document a paradigm shift from dual-agent GVHD prophylaxis (tacrolimus + methotrexate) to Orca-T + single-agent tacrolimus, reducing immunosuppressive burden and potentially allowing earlier immune reconstitution and stronger GvL activity. This is the most clinically advanced combination in this dataset.
CD33KO eHSPC + Gemtuzumab Ozogamicin ADC
VOR Biopharma's filings describe a "protect the graft, destroy the leukemia" platform: CD33-edited donor stem cell transplant followed by full-dose CD33-directed ADC therapy post-engraftment. This potentially enables dose-optimal ADC administration currently precluded by on-target hematopoietic toxicity in standard transplant settings.
Multi-Donor CD4-IL-10 + PBMC Co-infusion
TR1X data describe co-administration of PBMC with CD4-IL-10 cells, showing GvL activity is retained while GvHD suppression is active, supporting a modular cell combination approach. Multi-donor formulations match single-donor GvL preservation in preclinical ALL-bearing NSG mouse models.
S1P Modulator + alloHSCT Maintenance
Pleoselara filings describe mocravimod as a maintenance complement to alloHSCT in AML, with signals suggesting that post-transplant S1P receptor modulation may enhance GvL via lymphocyte trafficking redistribution. This would complement Treg-based GVHD suppression strategies, addressing relapse risk pharmacologically.
Who Holds the IP in Allogeneic Cell Therapy for GVHD?
Innovation activity in this dataset is predominantly patent-driven and concentrated among a small set of specialized cell therapy companies and academic medical centers. Orca Biosystems, Inc. (US) is the most represented assignee directly relevant to the research question, with filings across CA, BR, JP, and CN jurisdictions. The volume and jurisdictional breadth signal active global IP prosecution and commercial intent.
VOR Biopharma Inc. (US) holds CN and JP filings on CD33KO eHSPC technology, positioning the company as a direct IP holder in the engineered stem cell / antigen-shielding space for AML. Disc Medicine (US) holds a pending TW patent on HA-1/HA-2 TCR-T cell therapy covering AML, ALL, and MDS post-HCT — a targeted niche within the relapsed/refractory post-transplant space.
TR1X Inc. holds a CN pending patent on multi-donor CD4-IL-10 cells with preclinical GvL data in ALL mouse models. Millennium Pharmaceuticals (US) and Kymab Ltd. (UK) hold CN filings on anti-α4β7 integrin and anti-OX40L antibodies respectively. Academic institutions including Nottingham Trent University contribute disease biology and target identification. For a comprehensive assignee mapping, PatSnap Analytics provides landscape visualization across all jurisdictions. The European Patent Office and USPTO databases underpin the global filing coverage analyzed here.
Orca-T & Allogeneic Cell Therapy GVHD — Key Questions Answered
Orca-T is a precision allogeneic cell therapy product developed by Orca Biosystems, Inc. that employs highly purified regulatory T cells (Tregs) to control alloreactive immune responses while preserving graft-versus-tumor (GvT) immunity. The mechanism involves preparing a composite graft containing highly purified, polyclonal donor Tregs administered alongside a defined conventional T cell (Tcon) fraction. Naive conventional αβ-T cells are selectively depleted from the graft while memory T cells are preserved. Single-agent GVHD prophylaxis (tacrolimus) is used rather than dual-agent regimens, reducing immunosuppressive burden.
Orca Biosystems patent filings embed Phase 1b and Phase 2 clinical data: NCT01660607 (Phase 2, single-center, n=34) and NCT04013685 (Phase 1b, multi-center, n=103). A combined 137 high-risk hematologic malignancy patients received Orca-T through December 2021, with ≥100-day follow-up (range 27–1,988 days; median 341 days). GVHD and relapse-free survival (GRFS) at 1 year was superior to the CIBMTR historical comparator (n=375, 69 US transplant centers). Neutrophil and platelet engraftment occurred at medians of 12.5 and 15.5 days, respectively.
VOR Biopharma's approach involves genetically engineering donor HSPCs to delete or silence CD33 expression (CD33KO), thereby rendering the normal hematopoietic compartment insensitive to CD33-directed therapeutics such as gemtuzumab ozogamicin (Mylotarg). This enables full-dose CD33-targeted ADC therapy to be administered post-transplant to eradicate residual AML without off-target toxicity to engrafted donor cells. The CN filing specifies that CD33 editing efficiency of ≥45% and cell viability of ≥70% at 48 hours post-electroporation are the manufacturing acceptance criteria.
HA-1 and HA-2 are expressed on hematopoietic cells including AML, ALL, and MDS blasts but not on non-hematopoietic tissues, providing a tumor-selective window for TCR-engineered adoptive cell therapy post-HCT. Disc Medicine's approach addresses engineered T cells expressing TCRs specific for HA-1 and HA-2 for treatment of AML, ALL, and MDS in patients who have received prior HCT. This represents a post-transplant relapse-directed strategy distinct from GVHD prevention.
Acute GVHD of Grade 2–4 occurs in approximately 40–50% of patients receiving unrelated donor peripheral blood stem cell (PBSC) transplants following myeloablative conditioning. Despite calcineurin inhibitor (CNI) + methotrexate prophylaxis, GVHD develops in 30–50% of alloHSCT recipients, with Grade 2+ acute GVHD treated with corticosteroids as first-line therapy. Chronic GVHD further compounds long-term morbidity.
Retrieved results signal several combination strategies: Orca-T plus single-agent tacrolimus reduces immunosuppressive burden versus dual-agent prophylaxis. CD33KO eHSPC combined with gemtuzumab ozogamicin ADC enables dose-optimal post-transplant AML eradication. Multi-donor CD4-IL-10 cells co-administered with PBMCs preserve GvL while suppressing GVHD. S1P receptor modulator mocravimod as post-alloHSCT maintenance may enhance GvL via lymphocyte trafficking redistribution. RARA agonist plus venetoclax plus azacitidine combinations may serve as bridging strategies to achieve deeper remission prior to alloHSCT.
Still have questions? Let PatSnap Eureka answer them for you.
Ask Eureka About GVHD Cell Therapy PatentsAccelerate Your Allogeneic Cell Therapy Intelligence
From Orca-T Treg graft engineering to CD33KO eHSPC and HA-1/HA-2 TCR-T cell strategies — PatSnap Eureka maps the full GVHD reduction patent landscape across AML, ALL, and MDS in real time. Join 18,000+ innovators already using PatSnap Eureka to accelerate their R&D.
References
- Methods for allogeneic hematopoietic stem cell transplantation — Orca Biosystems, Inc., 2023, CA [Patent]
- Methods for allogeneic hematopoietic stem cell transplantation — Orca Biosystems, Inc. (Oruka Biosystems Inc.), 2025, JP [Patent]
- Methods for transplantation of allogeneic hematopoietic stem cells — Orca Biosystems, Inc., 2025, BR [Patent]
- Compositions and methods for hematopoietic stem cell transplantation — Orca Biosystems, Inc. (Aoka Biosystems Inc.), 2025, CN [Patent]
- Methods for allogeneic hematopoietic stem cell transplantation (Haokan CN filing) — Haokan Biosystems Inc., 2023, CN [Patent]
- Multi-donor CD4+ T cells expressing IL-10 and their uses — TR1X Inc., 2024, CN [Patent]
- Use of anti-HA-1 and anti-HA-2 binding proteins for treatment of AML, ALL, and MDS — Disc Medicine (Diskmed Medical Corporation), 2026, TW [Patent]
- Compositions and methods for treating hematopoietic malignancies — VOR Biopharma Inc., 2023, CN [Patent]
- Compositions and methods for treating hematopoietic malignancies — VOR Biopharma Inc., 2023, JP [Patent]
- Combination therapy dosing regimens — Encarata Inc. (Encarta Inc.), 2025, CN [Patent]
- Antibodies, uses, and methods — Kymab Ltd., 2018, CN [Patent]
- Methods for treating or preventing graft-versus-host disease — Millennium Pharmaceuticals, 2023, CN [Patent]
- Methods of treatment using S1P receptor modulators — Pleoselara Ltd., 2023, CN [Patent]
- Therapies for treating AML and uses of RARA agonists, hypomethylating agents, and BCL-2 inhibitors — Syros Pharmaceuticals, Inc., 2023, IL [Patent]
- Therapies for treating AML and uses of RARA agonists, hypomethylating agents, and BCL-2 inhibitors — Syros Pharmaceuticals, Inc., 2023, JP [Patent]
- WIPO — World Intellectual Property Organization: Global patent filing database
- European Patent Office (EPO) — Patent search and analytics
- United States Patent and Trademark Office (USPTO)
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report is derived from a limited set of patent and literature records retrieved across targeted searches and represents a snapshot of innovation signals within this dataset only. It should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.